Hi-Q and Shanghai Researchers Unveil Fucoidan's Promising Role in Halting Hepatocellular Carcinoma Progression

Hi-Q Marine Biotech, in collaboration with Shanghai Zhongshan Hospital of Fudan University and Institute of Liver Diseases, Shanghai Jiao Tong University, presents groundbreaking research on fucoidan's potential in combating hepatocellular carcinoma (HCC).
HCC as a main type of primary liver cancers has become one of the most deadly tumors because of its high morbidity and poor prognosis. In our study, we demonstrated that fucoidan contributes to inhibiting cell proliferation in vivo and in vitro, restraining cell motility and invasion and inducing cell cycle arrest and apoptosis. According to High-Throughput sequencing of long-non-coding RNA (lncRNA) in MHCC-97H cells treated with fucoidan, we found that 56 and 49 lncRNAs were correspondingly up- and down-regulated. LINC00261, which was related to the progression of tumor, was highly expressed in fucoidan treated MHCC-97H cells. Moreover, knocking down LINC00261 promoted cell proliferation by promoting the expression level of miR-522-3p, which further decreased the expression level of downstream SFRP2. Taken together, our results verified that fucoidan effectively inhibits the progression of HCC via causing lncRNA LINC00261 overexpression.

[Research Article]
Ma, Danhui, et al. “Fucoidan Inhibits the Progression of Hepatocellular Carcinoma via Causing LncRNA LINC00261 Overexpression.” Frontiers in Oncology, vol. 11, 2021, https://doi.org/10.3389/fonc.2021.653902